Dr. Daniel C. Chung

Our Retina International World Congress (RIWC24) takes place from the 5th – 8th June 2024 in the Dublin Royal Convention Centre, in the heart of Dublin city centre.

The theme of our upcoming Retina International World Congress 2024 (RIWC24) is ‘Targeting the Cure’ and our Scientific Committee has been working relentlessly to secure an impressive lineup of outstanding speakers to shed light on this research area.

As part of our Meet the Speaker series, we are proud to announce that we will have with us the distinguished speaker Dr. Daniel C. Chung, DO, MA, Chief Medical Officer at SparingVision and leader in the field of ocular gene therapy.

Headshot of Daniel Chung on a blue background image. Text: Retina International World Congress. Dublin Royal Convention Centre, Dublin, Ireland. RIWC24. DUBLIN: Targeting the Cure. JUNE 5-8, 2024. DR. DANIEL C. CHUNG, Chief Medical Officer, SparingVision. At the bottom of the image, there are the Fighting Blindness and Retina International logos

Dr. Chung has significant experience in Ocular Gene Therapies for Inherited Retinal Degenerations (IRDs) and was previously head of ophthalmic medical affairs at Spark Therapeutics, responsible for the development and approval of Luxturna™, the first in vivo gene therapy approved by the US Food and Drug Administration (FDΑ) for RPE65-related inherited retinal disease.

Dr. Chung will join us on June 7 to present on Gene Agnostic Therapeutic Approaches for IRDs and you can learn more about his work in his full bio below.

Stay tuned for more updates and registration details as we draw closer to this incredible gathering of the latest scientific research and innovation, set to take place in 2024.

Dr. Daniel C. Chung, DO, MA

Daniel C. Chung is the Chief Medical Officer at SparingVision, a genomic medicine company specialising in gene therapies for vision loss. He has significant experience in Ocular Gene Therapies for Inherited Retinal Diseases (IRDs), spanning all stages of their development; from pre-clinical studies through to clinical development and post-marketing activities.

Dr. Chung was previously head of ophthalmic medical affairs at Spark Therapeutics, responsible for the development and approval of Luxturna™, the first in vivo gene therapy approved by the US Food and Drug Administration (FDΑ) for RPE65 related inherited retinal disease. He also later led the medical affairs group responsible for its safe and efficient use in patients and has served as a subject matter expert companywide including patient advocacy, regulatory, pre-clinical, clinical, medical, payer and commercial/marketing groups.

Dr. Chung’s academic background includes a medical degree from the New York College of Osteopathic Medicine in 1994, followed by postgraduate training at the National Eye Institute, Summa Health Systems and Cole Eye Institute at the Cleveland Clinic Foundation. Before joining Spark, Dr Chung worked for 11 years at the Scheie Eye Institute within the Perelman School of Medicine at the University of Pennsylvania, specialising in gene-based therapies for IRDs and cilia mediated disease.

As a member of the executive team at SparingVision, Dr Chung will lead the clinical development and research of SPVN06 gene therapy which has the potential to stop the degeneration of cone photoreceptors and therefore prevent blindness. The aim is to treat a much wider population of patients with rod-cone dystrophies like Retinitis Pigmentosa (RP). Dr Chung will also be responsible for the clinical development of future additions to the product pipeline and will lead the education of the medical and SparingVision’s patient communities.